Chengdu Olymvax Biopharmaceuticals Third Quarter 2024 Earnings: EPS: CN¥0.078 (vs CN¥0.004 in 3Q 2023)

Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥160.4m (up 35% from 3Q 2023).
• Net income: CN¥32.0m (up by CN¥30.2m from 3Q 2023).
• Profit margin: 20% (up from 1.5% in 3Q 2023).
• EPS: CN¥0.078 (up from CN¥0.004 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chengdu Olymvax Biopharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are down 3.7% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Chengdu Olymvax Biopharmaceuticals' balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.